Ali Seifinejad

As a translational scientist , I bring over 10 years of experience in conducting research across both basic and clinical domains. The basic research discovery I made is currently undergoing clinical trials. My proficiency spans various neuroscientific areas, enabling me to address pivotal inquiries in diverse translational and clinical domains, resulting in publications in high-impact journals. During this path, I prepared, submitted, and received approval for many regulatory documents from both Swiss and EU (in Germany) authorities . In addition, I possess excellent leadership, project management, and collaborative skills. I am now seeking opportunities to further develop my expertise in an advanced environment, where I can continue advancing my career within the biomedical domain.

SELECTED PUBLICATIONS

• A. Seifinejad* et al., (2023). Epigenetic silencing of selected hypothalamic neuropeptides in narcolepsy with cataplexy. Proc. Natl. Acad. Sci (PNAS).
• A. Seifinejad, S. Li, M. Possovre, A. Vassalli, M. Tafti, (2020). Hypocretinergic interactions with the serotonergic system regulate REM sleep and cataplexy. Nature Communications.
• A. Seifinejad* et al., (2019). Molecular codes and in vitro generation of hypocretin and melanin concentrating hormone neurons. Proc. Natl. Acad. Sci (PNAS).

PATENT

METHODS FOR TREATING AND/OR PREVENTING HYPERSOMNIAS.
Tafti Mehdi, A. Seifinejad. (2021). Publication Number: WO/2021/078631

· 2023 InnoSTEP grant from innovation and technology transfer office of University of Lausanne.

· 2023 Research grant from Novartis Foundation for medical-biological Research.

· 2018 Research Seed money grant from Swiss University of applied sciences.